EGTA AM (Synonyms: EGTA Acetoxymethyl ester) |
カタログ番号GC43589
One-Click Copy Product Info
|
EGTA AMは、キレート化の動態が緩やかな膜透過性Ca2+キレート剤である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 99590-86-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
EGTA AMは、キレート化の動態が緩やかな膜透過性Ca2+キレート剤である。EGTA AMはバスアプリケーションにより細胞内に充填されることができ、したがって、グルタミン酸の非同期放出を引き起こすために必要なCa2+の緩やかな上昇を阻害することができる。EGTA AMによるカルシウムキレート化は透明帯による先体反応およびアポトーシスを抑制し、精子の運動性を高める。EGTA AMはカルシウムイオンのキレート化によるハイブリッド・オルガネラの形成につながる融合を抑制することができる。EGTA AMは低濃度では、アルツハイマー病の脳組織サンプル中のアミロイド斑を溶解することができる。EGTA AMは呼吸器系ムチンの物理化学的性質を変化させることで、M1/MUC5ACムチンの検出を促進し、それによって、抗M1モノクローナル抗体が反応するエピトープを露出させる。EGTA AMは、有害な酸化還元活性を持つ金属イオンと結合し、活性酸素および活性窒素物質を無害化することができ、触媒型抗酸化剤の開発に役立つ。
References:
[1] Li M J, Chang T W, Hung W C, et al. Cholinergic and glutamatergic transmission at synapses between pedunculopotine tegmental nucleus axonal terminals and A7 catecholamine cell group noradrenergic neurons in the rat[J]. Neuropharmacology, 2016, 110: 237-250.
[2] Ebrahimi B, Keshtgar S. The effects of EGTA on the quality of fresh and cryopreserved-thawed human spermatozoa[J]. Iranian Journal of Medical Sciences, 2020, 45(3): 188.
[3] Pryor P R, Mullock B M, Bright N A, et al. The role of intraorganellar Ca2+ in late endosome–lysosome heterotypic fusion and in the reformation of lysosomes from hybrid organelles[J]. The Journal of cell biology, 2000, 149(5): 1053-1062.
[4] Cherny R A, Legg J T, McLean C A, et al. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion[J]. Journal of Biological Chemistry, 1999, 274(33): 23223-23228.
[5] Roger P, Gascard J P, Bara J, et al. EGTA treatment of human airways in vitro unmasks M1/MUC5AC mucin in submucosal glands[J]. European Respiratory Journal, 2001, 18(1): 176-183.
[6] Fisher A E O, Hague T A, Clarke C L, et al. Catalytic superoxide scavenging by metal complexes of the calcium chelator EGTA and contrast agent EHPG[J]. Biochemical and biophysical research communications, 2004, 323(1): 163-167.
| Cas No. | 99590-86-0 | SDF | |
| 同義語 | EGTA Acetoxymethyl ester | ||
| Canonical SMILES | CC(OCOC(CN(CC(OCOC(C)=O)=O)CCOCCOCCN(CC(OCOC(C)=O)=O)CC(OCOC(C)=O)=O)=O)=O | ||
| Formula | C26H40N2O18 | M.Wt | 668.6 |
| 溶解度 | DMSO : 100 mg/mL (149.57 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4957 mL | 7.4783 mL | 14.9566 mL |
| 5 mM | 299.1 μL | 1.4957 mL | 2.9913 mL |
| 10 mM | 149.6 μL | 747.8 μL | 1.4957 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)